Transfusion and Apheresis Science最新文献

{"title":"Predictors of platelet count response following intravenous immunoglobulin use for maternal thrombocytopenia","authors":"Roy Khalife ,&nbsp;Bonnie Niu ,&nbsp;Iris Perelman ,&nbsp;Darine El-Chaâr ,&nbsp;Dean Fergusson ,&nbsp;Alan Karovitch ,&nbsp;Johnathan Mack ,&nbsp;Melanie Tokessy ,&nbsp;Kathryn E. Webert ,&nbsp;Alan Tinmouth","doi":"10.1016/j.transci.2025.104125","DOIUrl":"10.1016/j.transci.2025.104125","url":null,"abstract":"<div><h3>Background</h3><div>Thrombocytopenia in pregnancy may require administering intravenous immunoglobulin (IVIG), particularly when immune thrombocytopenia is suspected. However, the effectiveness of IVIG is not well-defined, creating a gap in optimal treatment strategies. This study aims to evaluate the efficacy of IVIG and identify predictors of platelet response in pregnant persons with moderate-to-severe thrombocytopenia, aiming to optimize clinical decisions and resource use.</div></div><div><h3>Methods</h3><div>We conducted a single-center retrospective cohort study of 79 pregnant persons with moderate-to-severe thrombocytopenia (platelets [PLT] &lt;100 ×10⁹/L) who received IVIG between 2007 and 2020. Data on maternal demographics, PLT counts, immature platelet fraction (IPF), and IVIG administration were collected. Logistic regression identified predictors of achieving a PLT ≥ 80 × 10⁹/L and an increment ≥ 20 × 10⁹/L following IVIG administration.</div></div><div><h3>Results</h3><div>The median incremental PLT response following IVIG administration was 16 × 10⁹/L, with 49.4 % achieving PLT ≥ 80 × 10⁹/L and 46.8 % achieving an increment ≥ 20 × 10⁹/L. Predictors of a favorable response included nadir PLT &lt; 30 × 10⁹/L (OR = 6.29), IPF &lt; 16 % (OR = 4.85), and pre-IVIG PLT &lt; 50 × 10⁹/L (OR = 8.67). Higher pre-IVIG PLT counts (70–100 ×10⁹/L) were associated with lower odds of achieving a significant PLT increment.</div></div><div><h3>Discussion</h3><div>IVIG effectively increases PLT counts in pregnant persons with severe thrombocytopenia, especially in those with a nadir PLT &lt; 30 × 10⁹/L, IPF &lt; 16 %, or pre-IVIG PLT &lt; 50 × 10⁹/L. This study highlights the importance of careful patient selection for IVIG to enhance outcomes and conserve resources. Future research should focus on prospective studies to refine treatment guidelines and resource stewardship of IVIG for maternal thrombocytopenia.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 3","pages":"Article 104125"},"PeriodicalIF":1.4,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transforming care: Patient insights on neurology-led peripheral plasma exchange service","authors":"Mahsa Layegh ,&nbsp;Agith Varghese ,&nbsp;Anna Yudina ,&nbsp;Ashwin Pinto ,&nbsp;Chinar Osman","doi":"10.1016/j.transci.2025.104121","DOIUrl":"10.1016/j.transci.2025.104121","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Therapeutic plasma exchange (TPE) is a highly efficacious treatment for a wide range of antibody-mediated neuroimmunological disorders. Practical difficulties of TPE via membrane filtration, which requires central venous access, have limited its use for neurology patients. The development of centrifugal plasma exchange (cTPE) machines has enabled treatment via peripheral venous access. We set up a neurology-led ambulatory day case peripheral plasma exchange service at the Wessex Neuroscience Centre in 2019 via cTPE machines. This study aims to evaluate the service based on patients' experience and satisfaction.</div></div><div><h3>Materials and method</h3><div>We retrospectively collected data for patients who received cTPE in our centre over a 20-month period. We designed a patient survey that included 15 questions based on Likert grading system. Patients were either given a QR code or were contacted by volunteers from the hospital to complete the questionnaire over the phone.</div></div><div><h3>Results</h3><div>47 out of the 72 eligible patients participated in the survey. All survey questions received a positive response of 80 % and above, with responses in the range of 90 %. All patients who completed the survey commented that they would recommend this service.</div></div><div><h3>Conclusion</h3><div>cTPE machines enable plasma exchange via peripheral venous access allowing treatment for ambulatory day case patients. This study provides evidence confirming the positive patient experience with cTPE services at the Wessex Neurosciences Centre and highlights the importance of establishing neurology-led cTPE units to deliver effective treatment for neuroimmunology patients.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 3","pages":"Article 104121"},"PeriodicalIF":1.4,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143860363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimation of ABO hemolytic disease of the fetus and newborn through gene frequency study and immunohematological characterization of the disease","authors":"Sudipta Sekhar Das ,&nbsp;Amrita Roy ,&nbsp;Sourav Mukherjee ,&nbsp;Sourav Chowdhury","doi":"10.1016/j.transci.2025.104120","DOIUrl":"10.1016/j.transci.2025.104120","url":null,"abstract":"<div><h3>Introduction</h3><div>The ABO-hemolytic disease of the fetus and newborn (HDFN) occurs when a blood group “O” mother carries a non-blood group “O” fetus. Seldom hyperbilirubinemia may occur, requiring treatment. We calculated the prevalence of ABO-HDN in our population and addressed the immunohematological tests required for its characterization.</div></div><div><h3>Methodology</h3><div>The frequency of ABO genes was arithmetically derived from the phenotype data. The probability of non-blood group “O” children born to blood group “O” mothers was estimated. Immunohematological investigations were performed and clinical and laboratory outcomes of each newborn were observed till discharge from hospital.</div></div><div><h3>Results</h3><div>A total of 913 group “O” mothers gave birth to non-group “O” children which resulted in 20 (2.19 %) cases of HDFN. Direct antiglobulin test (DAT) positivity due to IgG1 or IgG3 or both was observed in 15 (75 %) cases. All newborns received phototherapy and 7 (35 %) in addition required exchange transfusion. The correlation between mother Anti-A and Anti-B IgG titres and newborn DAT was strongly positive. With the increase in newborn DAT strength, the newborn hemoglobin and bilirubin were remarkably deranged. Significant improvements in all laboratory parameters were observed with treatment.</div></div><div><h3>Conclusion</h3><div>Estimation of gene frequency in a population can predict the probability of group “O” mothers giving birth to non-group “O” children. These calculations along with detailed clinical and laboratory investigations give the number of ABO-HDFN cases in the population. Correlation studies comprising of mother and newborn immunohematological and laboratory factors assess the severity of ABO-HDFN and help in the treatment and follow-up of patients.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 3","pages":"Article 104120"},"PeriodicalIF":1.4,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143851558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating strategic blood donor recruitment initiatives: Insights from King Fahd armed forces hospital experience","authors":"Waleed M. Bawazir ,&nbsp;Osama A. Alzahrani ,&nbsp;Ahmed G. Bukhari ,&nbsp;Raed I. Felimban ,&nbsp;Ahmed M. Alaqari ,&nbsp;Ahmed Y. Jubran ,&nbsp;Abdullah A. Almalki ,&nbsp;Wael A. Khallaf ,&nbsp;Ryan M. Alshehri ,&nbsp;Junaid H. Faqih ,&nbsp;Hadeel Al Sadoun ,&nbsp;Wajnat A. Tounsi ,&nbsp;Nora Y. Hakami ,&nbsp;Malik A. Altayar ,&nbsp;Mohammed M. Jalal","doi":"10.1016/j.transci.2025.104119","DOIUrl":"10.1016/j.transci.2025.104119","url":null,"abstract":"<div><h3>Background &amp; aims</h3><div>Ensuring a safe and sufficient blood supply requires effective recruitment strategies, particularly in post-pandemic contexts. This study examines the transition at King Fahd Armed Forces Hospital (KFAFH) from a predominantly patient-related donor base to a focus on volunteer-based mobile and app-facilitated donations. It evaluates key factors influencing this shift and explores the potential for applying this model nationally.</div></div><div><h3>Methods</h3><div>A quasi-experimental retrospective analysis was conducted using KFAFH donation records from 2014 to 2024. Donors were categorized by recruitment type (patient-related, military, mobile, app-based, staff, and other) and compared based on age, gender, first-time vs. repeat status, donation frequency, and infectious disease testing (IDT) outcomes. Donor eligibility criteria and donation intervals were also analyzed. A SWOT analysis evaluated the operational aspects of mobile campaigns, including recruitment strategies, collection sites, and incentive usage.</div></div><div><h3>Results</h3><div>From 2021–2024, mobile and app-based campaigns significantly increased voluntary donations, while patient-related donations decreased by over 50 %. Mobile donors were predominantly repeat donors aged 25–40, with a higher male participation rate. IDT reactivity rates were lower in mobile donors compared to patient-related donors. Mobile drives—held at businesses, schools, and community centers—were supported by targeted outreach, recurring events, and non-monetary incentives. The program demonstrated operational strengths but encountered logistical and resource challenges.</div></div><div><h3>Conclusions</h3><div>Mobile and technology-driven recruitment significantly increased voluntary donations and reduced dependence on patient-related donations at KFAFH. This model shows promise as a replicable strategy for building a more resilient and sustainable national blood supply system.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 3","pages":"Article 104119"},"PeriodicalIF":1.4,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refractory delayed-onset heparin induced thrombocytopenia (HIT) without thrombosis, treated with intravenous immunoglobulin","authors":"Gordana Tomac ,&nbsp;Ivona Horvat ,&nbsp;Jakša Babel ,&nbsp;Koraljka Gojčeta ,&nbsp;Milica Liker ,&nbsp;Ana Boban ,&nbsp;Ines Bojanić","doi":"10.1016/j.transci.2025.104118","DOIUrl":"10.1016/j.transci.2025.104118","url":null,"abstract":"<div><div>Heparin-induced thrombocytopenia (HIT) is a platelet activation syndrome characterized by the sudden onset of thrombocytopenia and/or thrombosis, induced by anti-platelet factor 4 (PF4)/heparin antibodies that cause platelet activation and destruction. Delayed-onset heparin-induced thrombocytopenia is a variant of HIT that occurs in less than 5 % of cases and is characterized by the onset of thrombocytopenia and/or thrombosis several days after heparin discontinuation. With treatment, the platelet count usually recovers within a week, but in up to 1 % of patients, thrombocytopenia persists for several weeks or months, which is referred to as refractory (persisting) HIT. Refractory delayed-onset HIT represents an important clinical entity because of its potential complications as well as the challenges and complexities in diagnostics and treatment. In the following case report, we present a case of a 69-year-old man diagnosed with refractory delayed-onset HIT, confirmed by a functional assay for platelet-activating anti-PF4/heparin antibodies, who prolonged platelet count recovery without evident signs of thrombosis and was successfully treated with intravenous immunoglobulin (IVIG). This case report provides important clinical and laboratory data necessary for the timely recognition, diagnosis, and treatment of refractory delayed-onset HIT. It also emphasizes the need to consider HIT variants and highlights the importance of early recognition and treatment to minimize complications such as thrombosis and bleeding.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 3","pages":"Article 104118"},"PeriodicalIF":1.4,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143830014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"T cell subgroup analysis and T cell exhaustion after autologous stem cell transplantation in lymphoma patients","authors":"Kayra Somay ,&nbsp;Özgür Albayrak ,&nbsp;Ali Burak Kızılırmak ,&nbsp;Tuba Akan ,&nbsp;Ümit Barbaros Üre ,&nbsp;Olga Meltem Akay ,&nbsp;Burhan Ferhanoğlu ,&nbsp;Elif Birtaş Ateşoğlu","doi":"10.1016/j.transci.2025.104117","DOIUrl":"10.1016/j.transci.2025.104117","url":null,"abstract":"<div><h3>Background</h3><div>Autologous stem cell transplantation (ASCT) is a common treatment option for relapsed/refractory (R/R) lymphomas and it is considered standard of care as primary consolidation therapy for some types of Non-Hodgkin Lymphomas (NHL). Although ASCT benefits patients by allowing cytoreduction with intensive chemotherapy and reconstituting with stem cells, the effects of immunological changes in T cell subgroups after ASCT are still poorly understood.</div></div><div><h3>Objectives</h3><div>We evaluated changes in frequencies of T cell subsets and T cells expressing some of the exhaustion markers (such as LAG-3 and PD-1) from peripheral blood samples before and after ASCT to investigate bone marrow reconstruction and whether exhaustion predicts relapse.</div></div><div><h3>Study design</h3><div>Blood samples were collected on the day before conditioning and at the 1st, 3rd, and 6th months post-ASCT. Flow cytometry analysis was conducted to examine T cell subgroup composition and exhaustion markers, including PD-1 and LAG-3. Additionally, functional analysis was performed using assays for IFN-g and TNF-a production. Furthermore, a CSFE proliferation assay was utilized to assess proliferation capacity.</div></div><div><h3>Results</h3><div>In our data set, dominant cells post-transplantation were memory cells, as the naïve cell population did not recover for 6 months. Both single and combined expressions of LAG-3 and PD-1 were found to be high before transplantation, and decreased after transplantation. However, LAG-3 and PD-1 expression increased in the 3rd and 6th month after transplantation respectively. These changes were more evident for the relapsed patients when compared to non-relapsed patients within 3 months follow-up time. Notably, the expression of inhibitory receptors in the relapsed patients was significantly higher at the first month post-transplantation. CD107a⁺ cytotoxic T lymphocytes (CTL), IFN-g⁺, TNF-a^.+ CTL and T helper lymphocyte (THL) populations significantly decreased in relapsed patients 3rd month after transplantation. Decreased proliferation capacities of CTLs and THLs were also observed in these patients.</div></div><div><h3>Conclusion</h3><div>These results suggest that increased surface PD-1 and LAG-3 expressions along with functional decline after 3 months of ASCT can be used as prognostic data about the relapse status of transplant patients.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 3","pages":"Article 104117"},"PeriodicalIF":1.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weak D testing might be discontinued for RhD-negative blood donors with C and E negative phenotypes in the Indian population","authors":"Ayesha Sinha ,&nbsp;Sabita Basu ,&nbsp;Debapriya Basu ,&nbsp;Mahua Reddy ,&nbsp;Mercy Rophina ,&nbsp;Vinod Scaria ,&nbsp;Suvro Sankha Datta","doi":"10.1016/j.transci.2025.104116","DOIUrl":"10.1016/j.transci.2025.104116","url":null,"abstract":"<div><h3>Background</h3><div>Although serological testing to determine weak D status using the antihuman globulin reagent has been phased out for RhD-negative donors in many countries after the availability of <em>RHD</em> genotyping, it is routinely performed in India. However, weak D testing is a resource-intensive and time-consuming process. We devised a new algorithm for weak D testing in RhD-negative blood donors by performing CcEe phenotyping followed by weak D testing in only C+ and/or E + samples and compared it with the existing protocol in terms of time and cost-effectiveness.</div></div><div><h3>Method</h3><div>In this observational study, we tested 500 samples of RhD-negative blood donors over one year in India. The existing and new algorithms were compared, and the agreement was calculated in terms of the test results, time required for testing, and total cost involved. The RhD type, weak D status, and CcEe phenotypes were determined using the conventional tube technique. An adsorption-elution test was performed to check for the Del phenotype. We conducted <em>RHD</em> genotyping for all samples negative for weak D testing.</div></div><div><h3>Results</h3><div>The proposed algorithm showed perfect agreement with the existing protocol (agreement = 100 %; κ= 1.00). By applying the new algorithm, we could reduce 71.63 % of testing time and 24 % of total cost without missing any weak D positive samples in blood donors.</div></div><div><h3>Conclusions</h3><div>Weak D testing might be discontinued for RhD-negative blood donors with C and E negative phenotypes in the Indian population and could be restricted to only C+ and/or E + phenotypes, which seems to be a time- and cost-effective testing strategy.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 3","pages":"Article 104116"},"PeriodicalIF":1.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Twenty years of the four-factor prothrombin complex concentrate Octaplex/Balfaxar: A narrative review","authors":"Keyvan Karkouti ,&nbsp;Michelle Gareis ,&nbsp;Chenxi Li ,&nbsp;Hubert Brandstätter ,&nbsp;Alexander Pichotta ,&nbsp;Trupti Mehta Shah ,&nbsp;Joshua N. Goldstein","doi":"10.1016/j.transci.2025.104115","DOIUrl":"10.1016/j.transci.2025.104115","url":null,"abstract":"<div><div>Prothrombin complex concentrate (PCC) is used to boost thrombin potential, support clot formation, and aid in the treatment and prophylaxis of bleeding. The two main forms of PCC are three-factor (3 F-PCC; comprising coagulation factors II, IX, and X) and four-factor (4F-PCC; factors II, VII, IX, X), which contain 25 times the clotting factors found in human plasma. This narrative review summarizes published efficacy and safety data on one 4F-PCC (Octaplex/Balfaxar, Octapharma) within its recognized uses and explores potential applications across different clinical contexts. Clinically available for &gt; 20 years, Octaplex/Balfaxar is supplied as a freeze-dried powder for reconstitution and intravenous infusion. This 4F-PCC contains non-activated forms of coagulation factors as well as anticoagulant proteins C and S, potentially affording a balanced hemostatic effect and mitigating thrombosis risk. Production involves two virus inactivation/removal steps: solvent/detergent treatment and nanofiltration. 4F-PCC is approved for acquired deficiency of vitamin K-dependent clotting factors, such as those induced by vitamin K antagonists (VKAs, e.g., warfarin), and for congenital deficiency of factors II and X. Five published trials in 444 adult patients demonstrated the efficacy of 4F-PCC in VKA reversal, reducing the international normalized ratio (INR) with only two potentially treatment-related thrombotic events reported. While 4F-PCC dosing is currently indicated to be INR-guided, emerging evidence supports fixed dosing as an alternative to conventional weight-based dosing for VKA reversal. Recent guidelines support 4 F-PCC use for direct oral anticoagulant-associated bleeding, cardiac surgery and trauma/emergencies. Ongoing studies will further clarify the efficacy and safety of 4 F-PCC beyond its approved indications.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 3","pages":"Article 104115"},"PeriodicalIF":1.4,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision diagnostics in Transfusion Medicine: Advancing accuracy in Bombay blood group typing through molecular methods","authors":"Shamee Shastry ,&nbsp;Akshay Chopra ,&nbsp;Yew-Wah Liew ,&nbsp;Glenda Millard ,&nbsp;Deepika Chenna ,&nbsp;Ganesh Mohan ,&nbsp;Deep Madkaiker","doi":"10.1016/j.transci.2025.104114","DOIUrl":"10.1016/j.transci.2025.104114","url":null,"abstract":"<div><h3>Background</h3><div>Integration of precision diagnosis in Immunohaematology and Transfusion Medicine has led to the development of more refined blood typing and crossmatching techniques, ensuring improved accuracy of blood group determination, thereby reducing the incidence of transfusion reactions and enhancing patient safety. It can also help resolve complex discrepancies noted in serological testing methods.</div></div><div><h3>Study design and methods</h3><div>The blood grouping of a 40 year old female patient done as a part of routine health check using column agglutination technology showed a O group phenotype with additional reaction with O cells in the serum group. Anti-H lectin study confirmed the absence of H antigen, with a Lewis Le(a+b-) phenotype, typing the patient as Classical Bombay phenotype. Further molecular workup was performed.</div></div><div><h3>Results</h3><div>An <em>in-house</em> designed panel enabling comprehensive genotyping for 45 blood group systems and transcription factors <em>KLF1</em> and <em>GATA1</em> was used<em>.</em> Sequencing covering the ABO gene predicted the presence of the <em>ABO*O.01.01</em> and <em>ABO*O.01.02</em> alleles and the group O phenotype. Combined results of the sequencing analysis identified <em>ABO*O.01.01/*O.01.02</em>, <em>FUT1*01N.09/*01N.09</em> and <em>FUT2*01/*01</em> with the predicted phenotype of H-deficient; secretor (para-Bombay). Oh-secretor shows the patient is genetically a ParaBombay since there is an active secretor gene, but phenotyped as Le(a+b-) due to the reduction in Lewis enzyme function by the FUT3 mutations. Hence the patient is classified as a paraBombay, even though the Lewis phenotype make the patient appeared to be a classical Bombay.</div></div><div><h3>Conclusion</h3><div>Integration of precision diagnostics into transfusion therapy improves transplant and transfusion safety.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 3","pages":"Article 104114"},"PeriodicalIF":1.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of transfusion transmitted infections by mode of donation and remuneration status among blood donors in Georgia, 2018–2023","authors":"Ketevan Shermadini ,&nbsp;Evan M. Bloch ,&nbsp;Shaun Shadaker ,&nbsp;Maia Alkhazashvili ,&nbsp;Nazibrola Chitadze ,&nbsp;Sophia Surguladze ,&nbsp;Irinka Tskhomelidze ,&nbsp;Vladimer Getia ,&nbsp;Ekaterine Adamia ,&nbsp;Rania A. Tohme ,&nbsp;Tamar Gabunia","doi":"10.1016/j.transci.2025.104110","DOIUrl":"10.1016/j.transci.2025.104110","url":null,"abstract":"<div><div>Global reform of blood transfusion services is underway in the country of Georgia. New legislation mandates exclusive collection of blood from non-remunerated blood donors in Georgia by July 2025. Retrospective data (2018–2023) from the National Blood Donor Registry were analyzed. The prevalence was calculated for human immunodeficiency virus (HIV) antigen/antibody (Ag/Ab), hepatitis C virus antibody (anti-HCV), hepatitis B surface antigen (HBsAg). Results were stratified by remuneration status and mode of donation. Descriptive analysis was performed to elucidate differences in positivity by year and donor type. During 2018–2023, there were a total of 548,530 donations from 221,492 blood donors in Georgia; 68.3 % of donors were male and the median age was 34 years (interquartile range: 26<img>44). Overall, 17.0 % were paid, 24.9 % were replacement, 47.4 % were voluntary non-remunerated blood donors (VNRBD), and 10.7 % had ≥ 2 donations of varying remuneration type. Paid donors had an average of 2.5 donations per year, compared to 1.0 for replacement, and 1.1 for VNRBDs<em><strong>.</strong></em> During 2018–2023, the proportions of paid donors decreased (38.8–22.1 %); the proportions of replacement (19.1–26.0 %) and VNRBDs (38.7–48.3 %) increased. Among first-time donors, prevalence decreased during 2018–2023 for anti-HCV (2.0–0.9 %) but were stable for HBsAg (range: 1.9 %-2.1 %) and anti-HIV (range: 0.1 %-0.2 %). Among repeat donors, prevalence of anti-HCV decreased (from 0.3 % to 0.2 %) while rates were stable for anti-HIV (0.04 %-0.1 %), and HBsAg (0.1 % in all years). The findings underscore the importance of donor retention in concert with efforts to attain exclusive VNRBD.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 3","pages":"Article 104110"},"PeriodicalIF":1.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}